Inquiry
Form loading...

Sotagliflozin 1018899-04-1 type 2 diabetes

IUPAC Name:(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol
Molecular Weight:424.94
Molecular Formula:C21H25ClO5S
Quality Standard:In House

    Product Specification

    Appearance: White to Off-white powder or crystallization
    Identification: HPLC、IR
    Water: ≤0.5%
    Related impurity: Any single impurity≤0.30%、Total impurities≤2.0%
    Purity: ≥98.0%

    description1

    PRODUCT DESCRIPTION

    Sogliflozin LX-4211 is a dual inhibitor of SGLT1/SGLT2, which has a new hypoglycemic mechanism. Previous studies have proved that it is effective in both type 1 diabetes and type 2 diabetes. In the three key multicenter phase III clinical studies of sogliflozin as an adjunctive insulin therapy for type 1 diabetes, the sogliflozin group reached the end point of the trial, and no severe hypoglycemia or other SAEs occurred during the study, which provided a clinical basis for the approval of sogliflozin as an adjunctive insulin therapy for type 1 diabetes.

    Sogliflozin LX-4211 is a new oral diabetes drug jointly developed by Sanofi and Rescan. This drug, as a dual inhibitor of SGLT-1 and SGLT-2, can lower postprandial blood sugar, increase GLP-1, and promote the excretion of urine sugar. Mechanism of action

    Mechanism of action: There are two main types of SGLT, namely SGLT1 and SGLT2. SGLT1 is mainly expressed in the brush like border of the small intestine and the S3 segment of the renal proximal tubules, with a small amount expressed in the heart, trachea, and brain. It is mainly responsible for transporting glucose and galactose in the intestinal cavity and reabsorbing glucose that has not been reabsorbed by SGLT2 in the renal proximal tubules. SGLT2 is specifically expressed in the S1 segment of the renal proximal tubules and is responsible for the reabsorption of glucose in the original urine by the renal proximal tubules, mediating approximately 90% of renal chemobook glucose reabsorption. The mechanism of action of SGLT2 inhibitors that have been marketed is mainly through selective inhibition of SGLT2, reducing glucose reabsorption in proximal renal tubules, increasing urine glucose excretion, and lowering blood sugar levels. Suogliflozin LX-4211, as a dual inhibitor of SGLT1/SGLT2, can inhibit SGLT2 and increase glucose excretion, as well as inhibit SGLT1 and reduce glucose entering the gastrointestinal tract, effectively lowering blood sugar.